DNA methylation profile at the DNMT3L promoter: a potential biomarker for cervical cancer.

DNA methylation profile at the DNMT3L promoter: a potential biomarker for cervical cancer. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

DNA methylation profile at the DNMT3L promoter: a potential biomarker for cervical cancer. Abstract Text:

Gopinathan Gokul,Bhimana Gautami,Surapaneni Malathi,A Pavani Sowjanya,Usha Rani Poli,Meenakshi Jain,Gayatri Ramakrishna,Sanjeev Khosla,Gopinathan Gokul,Bhimana Gautami,Surapaneni Malathi,A Pavani Sowjanya,Usha Rani Poli,Meenakshi Jain,Gayatri Ramakrishna,Sanjeev Khosla,Gopinathan Gokul,Bhimana Gautami,Surapaneni Malathi,A Pavani Sowjanya,Usha Rani Poli,Meenakshi Jain,Gayatri Ramakrishna,Sanjeev Khosla,

Epigenetic events play a prominent role during cancer development. This is evident from the fact that almost all cancer types show aberrant DNA methylation. These abnormal DNA methylation levels are not restricted to just a few genes but affect the whole genome. Previous studies have shown genome-wide DNA hypomethylation and gene-specific hypermethylation to be a hallmark of most cancers. Molecules like DNA methyltransferase act as effectors of epigenetic reprogramming. In the present study we have examined the possibility that the reprogramming genes themselves undergo epigenetic modifications reflecting their changed transcriptional status during cancer development. Comparison of DNA methylation status between the normal and cervical cancer samples was carried out at the promoters of a few reprogramming molecules. Our study revealed statistically significant DNA methylation differences within the promoter of DNMT3L. A regulator of de novo DNA methyltransferases DNMT3A and DNMT3B, DNMT3L promoter was found to have lost DNA methylation to varying levels in 14 out of 15 cancer cervix samples analysed. The present study highlights the importance of DNA methylation profile at DNMT3L promoter not only as a promising biomarker for cervical cancer, which is the second most common cancer among women worldwide, but also provides insight into the possible role of DNMT3L in cancer development.

DNA methylation profile at the DNMT3L promoter: a potential biomarker for cervical cancer. Publishing Authors By Initials

G Gokul,B Gautami,S Malathi,AP Sowjanya,UR Poli,M Jain,G Ramakrishna,S Khosla,G Gokul,B Gautami,S Malathi,AP Sowjanya,UR Poli,M Jain,G Ramakrishna,S Khosla,G Gokul,B Gautami,S Malathi,AP Sowjanya,UR Poli,M Jain,G Ramakrishna,S Khosla,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

DNA methylation profile at the DNMT3L promoter: a potential biomarker for cervical cancer. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Epigenetics : official journal of the DNA Methylat

VOLUME: 2

Page Numbers: 80-5

Journal Abbreviation:

ISSN: 1559-2308

DAY: 7

MONTH: 12

YEAR: 2006

DNA methylation profile at the DNMT3L promoter: a potential biomarker for cervical cancer. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 101265293

DNA methylation profile at the DNMT3L promoter: a potential biomarker for cervical cancer. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: DNA methylation profile at the DNMT3L promoter: a potential biomarker for cervical cancer. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for DNA methylation profile at the DNMT3L promoter: a potential biomarker for cervical cancer.

AFFILIATION: Laboratory of Mammalian Genetics, Centre for DNA Fingerprinting and Diagnostics (CDFD), Nacharam, Hyderabad, India.

Country: United States

AGENCY: United Kingdom Wellcome T

GRANT: 073417

ACRONYM:

MEDLINETA: Epigenetics

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

DNA methylation profile at the DNMT3L promoter: a potential biomarker for cervical cancer Related Publications

• A Cretaceous hoofed mammal from India.
• A population-based assessment of rates of bone loss at multiple skeletal sites: evidence for substantial trabecular bone loss in young adult women and men.
• A report of two 'traumatic encephaloceles'; an unrecognized entity.
• A scaleable manufacturing process for pro-EP-B2, a cysteine protease from barley indicated for celiac sprue.
• Assessment of gene regulation by bone morphogenetic protein 2 in human marrow stromal cells using gene array technology.
• Bioassay-guided evolution of glycosylated macrolide antibiotics in Escherichia coli.
• Characterization of circulating osteoblast lineage cells in humans.
• Combination enzyme therapy for gastric digestion of dietary gluten in patients with celiac sprue.
• Contribution of in vivo structural measurements and load/strength ratios to the determination of forearm fracture risk in postmenopausal women.
• DNA methylation profile at the DNMT3L promoter: a potential biomarker for cervical cancer.
• Does reduced skeletal loading account for age-related bone loss?
• Effects of loss of classical estrogen response element signaling on bone in male mice.
• Enhancement of dietary protein digestion by conjugated bile acids.
• High serum IGFBP-2 is predictive of increased bone turnover in aging men and women.
• High-trauma fractures and bone mineral density.
• Increased incidence of in-stent thrombosis related to cocaine use: case series and review of literature.
• Long-term fracture risk among women with proven endometriosis.
• MIB-1 immunolabeling: a valuable marker in prediction of benign recurring meningiomas.
• Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines.
• Production of ansamycin polyketide precursors in Escherichia coli.
• Solution structure and proposed domain domain recognition interface of an acyl carrier protein domain from a modular polyketide synthase.
• Structural determinants of vertebral fracture risk.
• Structure-activity relationship analysis of the selective inhibition of transglutaminase 2 by dihydroisoxazoles.
• Structure-activity relationships of semisynthetic mumbaistatin analogs.
• Structure-based design of alpha-amido aldehyde containing gluten peptide analogues as modulators of HLA-DQ2 and transglutaminase 2.
• Structure-based dissociation of a type I polyketide synthase module.
• Substrate tolerance of module 6 of the epothilone synthetase.
• Synthesis and biological activity of novel pyranopyrones derived from engineered aromatic polyketides.
• The skeletal response to estrogen is impaired in female but not in male steroid receptor coactivator (SRC)-1 knock out mice.
• Transglutaminase 2 undergoes a large conformational change upon activation.